Responding to Diseases in Real-time

Registration is Closed

Time & Location

Aug 05, 2020, 11:00 AM GMT+8
Full Event: https://biturl.top/3eMVNb

About The Event

Full Event: https://biturl.top/3eMVNb

Session Insights: TBA

As the world struggles to deal with disruptions brought about by a major pandemic, the race to finding a cure for COVID-19 is in full swing across the globe.  This race has dominated by the largest, most well-resourced pharmaceuticals and labs, with the exception of a few smaller, more nimble start-ups that have bucked this trend. Earlier in June, Tychan Pte Ltd became the first in Singapore to kick off human clinical trials for a COVID-19 monoclonal antibody, taking only 4 months to do so - achieving all this without the same resources or capital of a large pharmaceutical!  Together with A*StartCentral, we're exceptionally pleased to have in conversation Prof. Eng Eong Ooi, Founder of Tychan and Professor at Duke-NUS Medical School as we hear how Tychan responds to diseases in real-time, and what enables them to overcome the odds.

Share This Event

  • Facebook - White Circle
  • Hello Tomorrow Singapore LinkedIn
  • Hello Tomorrow Singapore - Twitter

© 2020 Hello Tomorrow Singapore